Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

VCYT

Veracyte Inc

May 15 • 04:00PM ET

23.55

Dollar change +0.53
Percentage change 2.30	%

Healthcare • Diagnostics & Research • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: ARKK VTI ARKG VB IWM VXF VBK IWN ARKW IBB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.93	Insider Own	0.89%	Shs Outstand	76.45M	Perf Week	17.05%
Market Cap	1.80B	Forward P/E	246.06	EPS next Y	0.10	Insider Trans	-1.54%	Shs Float	75.77M	Perf Month	24.47%
Income	-68.18M	PEG	-	EPS next Q	-0.04	Inst Own	105.38%	Short Float	5.80%	Perf Quarter	-7.76%
Sales	375.47M	P/S	4.80	EPS this Y	89.22%	Inst Trans	0.35%	Short Ratio	6.00	Perf Half Y	2.61%
Book/sh	14.64	P/B	1.61	EPS next Y	187.01%	ROA	-5.78%	Short Interest	4.39M	Perf Year	-6.18%
Cash/sh	2.74	P/C	8.61	EPS next 5Y	-	ROE	-6.20%	52W Range	18.61 - 30.52	Perf YTD	-14.39%
Dividend Est.	-	P/FCF	68.38	EPS past 5Y	-10.52%	ROI	-6.05%	52W High	-22.84%	Beta	1.72
Dividend TTM	-	Quick Ratio	4.69	Sales past 5Y	34.42%	Gross Margin	62.24%	52W Low	26.54%	ATR (14)	0.98
Dividend Ex-Date	-	Current Ratio	5.00	EPS Y/Y TTM	-122.18%	Oper. Margin	-1.42%	RSI (14)	69.47	Volatility	4.66% 4.39%
Employees	815	Debt/Eq	0.01	Sales Y/Y TTM	20.66%	Profit Margin	-18.16%	Recom	1.89	Target Price	29.83
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	77.79%	Payout	-	Rel Volume	1.01	Prev Close	23.02
Sales Surprise	3.74%	EPS Surprise	87.42%	Sales Q/Q	17.50%	Earnings	May 07 AMC	Avg Volume	731.87K	Price	23.55
SMA20	16.00%	SMA50	12.69%	SMA200	-1.07%	Trades		Volume	737,880	Change	2.30%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-23-24	Reiterated	Needham	Buy	$30 → $33
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$33
Jan-07-22	Initiated	Stephens	Overweight	$52
Nov-18-21	Resumed	Goldman	Buy	$60
Jun-15-21	Initiated	Raymond James	Outperform	$45
Feb-18-21	Resumed	Needham	Buy	$88
Jan-28-21	Initiated	Truist	Buy	$61
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight	$48
Sep-09-20	Initiated	Morgan Stanley	Underweight	$35
Jul-31-19	Initiated	Lake Street	Buy	$35
Jul-02-19	Initiated	Needham	Buy	$33
Nov-29-18	Downgrade	Janney	Buy → Neutral
Oct-31-18	Upgrade	Janney	Neutral → Buy
Nov-07-17	Downgrade	Piper Jaffray	Overweight → Neutral
Nov-07-17	Downgrade	Janney	Buy → Neutral
Aug-31-17	Resumed	BTIG Research	Buy	$13
Nov-14-16	Resumed	Leerink Partners	Outperform	$12
Dec-18-15	Initiated	Cantor Fitzgerald	Buy	$13
Jun-11-15	Reiterated	Leerink Partners	Outperform	$11 → $13

Show Previous Ratings

Today 05:04PM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire)
May-13-24 09:55AM	Wall Street Analysts Believe Veracyte (VCYT) Could Rally 39.59%: Here's is How to Trade (Zacks) +5.29%
May-08-24 03:13PM	Veracyte, Inc. (NASDAQ:VCYT) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:55AM	Veracyte (VCYT) Reports Narrower Q1 Loss, Raises '24 Sales View (Zacks)
07:12AM	Q1 2024 Veracyte Inc Earnings Call (Thomson Reuters StreetEvents)
03:48AM	Loading…
03:48AM	Veracyte Inc (VCYT) (Q1 2024) Earnings Call Transcript Highlights: Strong Start with Revenue ... (GuruFocus.com)
May-07-24 10:55PM	VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:13PM	Veracyte: Q1 Earnings Snapshot (Associated Press Finance)
06:00PM	Veracyte Inc (VCYT) Q1 2024 Earnings: Surpasses Revenue Forecasts with Strong Test Performance (GuruFocus.com)
04:05PM	Veracyte Announces First Quarter 2024 Financial Results (Business Wire)
May-06-24 04:05PM	14 Studies Presented at AUA 2024 Show Decipher Tests Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding (Business Wire)
Apr-22-24 05:00PM	Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024 (Business Wire)
08:30AM	New Study Shows Veracytes Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance (Business Wire)
Apr-16-24 08:30AM	Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024 (Business Wire)
Apr-02-24 10:33AM	What Makes Veracyte (VCYT) a Lucrative Investment? (Insider Monkey) -5.22%
05:55PM	Loading…
Feb-27-24 05:55PM	Veracytes Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines (Business Wire)
Feb-26-24 03:20PM	7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff (InvestorPlace) +6.22%
Feb-23-24 11:10AM	Veracyte, Inc. (NASDAQ:VCYT) Q4 2023 Earnings Call Transcript (Insider Monkey) -8.87%
07:43AM	Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands (Zacks)
07:37AM	Q4 2023 Veracyte Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-22-24 06:05PM	Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:03PM	Veracyte: Q4 Earnings Snapshot (Associated Press Finance)
04:40PM	Veracyte Inc (VCYT) Reports 22% Revenue Growth in 2023, Maintains Positive Cash Flow Outlook (GuruFocus.com)
04:05PM	Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results (Business Wire)
Feb-21-24 05:00PM	Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference (Business Wire)
Feb-08-24 08:00AM	Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024 (Business Wire)
Feb-06-24 08:15AM	Veracyte Completes Acquisition of C2i Genomics (Business Wire)
Jan-08-24 08:00AM	Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform (Business Wire) +13.10%
Dec-12-23 04:30PM	Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-01-23 04:05PM	Real-World Data Presented at SUO 2023 Show that Veracytes Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress (Business Wire)
08:30AM	Loading…
Nov-29-23 08:30AM	Clinical Validation Data Published in CHEST Demonstrate that Veracytes Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules (Business Wire)
Nov-22-23 08:30AM	Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023 (Business Wire)
Nov-08-23 04:39PM	Veracyte, Inc. (NASDAQ:VCYT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 04:57PM	Veracyte: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Veracyte Announces Third Quarter 2023 Financial Results (Business Wire)
04:00PM	Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally (Business Wire)
Nov-02-23 08:15AM	Veracyte to Participate in the Stephens Annual Investment Conference (Business Wire) +6.13%
Oct-27-23 08:30AM	Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development (Business Wire)
Oct-26-23 02:50PM	7 Undervalued Stocks That Analysts Love Right Now (InvestorPlace)
Oct-17-23 08:15AM	Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023 (Business Wire)
Oct-16-23 10:43AM	16 Best Stocks to Buy and Hold for the Next 15 Years According to Cathie Woods Portfolio (Insider Monkey)
Oct-12-23 09:00AM	New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracytes Envisia Genomic Classifier for Patients with Interstitial Lung Disease (Business Wire) -5.82%
Oct-04-23 04:05PM	New Data from Phase 3 Trial Further Validate Prognostic Value of Veracytes Decipher Prostate Genomic Classifier (Business Wire)
Sep-28-23 04:05PM	New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracytes Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer (Business Wire)
08:15AM	Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023 (Business Wire)
Sep-27-23 09:00AM	Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer (Business Wire)
Sep-21-23 04:05PM	Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting (Business Wire)
Sep-07-23 04:05PM	Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Companys Tests (Business Wire)
Sep-06-23 08:15AM	Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies (Business Wire)
Sep-02-23 06:15AM	Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors? (Motley Fool)
Aug-29-23 08:15AM	Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (Business Wire)
Aug-22-23 08:15AM	Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer (Business Wire)
Aug-15-23 04:15PM	Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego (Business Wire)
Aug-08-23 06:05PM	Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:55PM	Veracyte: Q2 Earnings Snapshot (AP Finance)
04:05PM	Veracyte Announces Second Quarter 2023 Financial Results (Business Wire)
Aug-01-23 08:15AM	Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracytes Decipher Prostate Genomic Classifier in Prostate Cancer Treatment (Business Wire)
Jul-19-23 05:00PM	Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023 (Business Wire)
Jul-08-23 08:43PM	Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom (InvestorPlace)
Jun-20-23 08:31AM	New Data Suggest Veracytes Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer (Business Wire)
Jun-12-23 08:31AM	Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023 (Business Wire)
May-30-23 06:56AM	Veracyte, Inc.'s (NASDAQ:VCYT) Revenues Are Not Doing Enough For Some Investors (Simply Wall St.)
May-25-23 05:13PM	New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracytes Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer (Business Wire)
May-24-23 09:00AM	New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracytes Genomic Tests in Interstitial Lung Disease and Lung Cancer (Business Wire)
May-23-23 05:00PM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire)
May-22-23 07:30AM	Here's Why This Little-Known Growth Stock Is a Buy (Motley Fool) +7.79%
May-12-23 06:15AM	Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer (Business Wire)
May-05-23 01:59PM	Veracyte, Inc. (NASDAQ:VCYT) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-04-23 06:25PM	Veracyte (VCYT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Veracyte Announces First Quarter 2023 Financial Results (Business Wire)
09:45AM	New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules (Business Wire)
May-03-23 05:44PM	New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients (Business Wire)
08:30AM	Veracyte Announces Release of Inaugural ESG Report (Business Wire)
May-02-23 04:05PM	Data Published in "The Red Journal" Validate Clinical Utility of Veracytes Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer (Business Wire) -8.23%
May-01-23 05:35PM	Three Abstracts Focusing on the Clinical Utility of Veracytes Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference (Business Wire)
Apr-29-23 04:31PM	Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracytes Decipher Prostate Genomic Classifier (Business Wire)
Apr-27-23 04:05PM	Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting (Business Wire)
10:02AM	Will Veracyte (VCYT) Report Negative Earnings Next Week? What You Should Know (Zacks)
09:55AM	Wall Street Analysts See a 40.19% Upside in Veracyte (VCYT): Can the Stock Really Move This High? (Zacks)
Apr-18-23 09:48AM	The five-year returns have been strong for Veracyte (NASDAQ:VCYT) shareholders despite underlying losses increasing (Simply Wall St.)
Apr-17-23 08:30AM	New Data Reinforce Ability of Veracytes Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification (Business Wire)
Apr-13-23 05:00PM	Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023 (Business Wire) +7.24%
Apr-12-23 08:30AM	Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting (Business Wire)
Mar-23-23 06:54AM	Estimating The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT) (Simply Wall St.)
Mar-15-23 04:15PM	Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Companys Multi-Omics Capabilities and Tools for Biopharma Partners (Business Wire)
11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace)
Mar-11-23 12:11PM	Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank (Business Wire)
Mar-10-23 09:30AM	Double-Digit Sales Growth: Is This Stock a Convincing Buy for Growth Investors? (Motley Fool) -8.78%
Feb-27-23 05:00PM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire)
Feb-24-23 05:42AM	We're Interested To See How Veracyte (NASDAQ:VCYT) Uses Its Cash Hoard To Grow (Simply Wall St.)
Feb-22-23 06:15PM	Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +5.19%
04:05PM	Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results (Business Wire)
Feb-15-23 08:36AM	Data Published in "The Red Journal" Validate Prognostic Value of Veracytes Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer (Business Wire)
Feb-13-23 05:23PM	New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment (Business Wire)
10:14AM	Stay Long and Strong: Billionaire Ken Fisher Snaps Up These 2 Strong Buy Stocks (TipRanks)
Feb-06-23 05:00PM	Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023 (Business Wire)
Feb-01-23 04:05PM	Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium (Business Wire)
08:32AM	Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules (Business Wire)
Jan-24-23 10:23AM	Better Long-Term Buy in 2023: Exact Sciences or Veracyte? (Motley Fool)
Jan-23-23 09:00AM	Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors (GlobeNewswire) +5.75%

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
EASTHAM KARIN	Director	Apr 01 '24	Option Exercise	13.19	10,000	131,900	43,125	Apr 02 04:17 PM
EASTHAM KARIN	Director	Apr 01 '24	Sale	21.65	10,000	216,528	33,125	Apr 02 04:17 PM
JONES EVAN/ FA	Director	Mar 01 '24	Option Exercise	13.19	10,000	131,900	47,601	Mar 05 05:28 PM
JONES EVAN/ FA	Director	Mar 01 '24	Sale	24.36	10,000	243,599	37,601	Mar 05 05:28 PM
JONES EVAN/ FA	Director	Jul 19 '23	Sale	30.17	3,090	93,232	35,173	Jul 24 05:06 PM
JONES EVAN/ FA	Director	Jul 19 '23	Sale	30.14	838	25,257	37,601	Jul 24 05:06 PM
BISHOP JOHN L	Director	Jul 18 '23	Option Exercise	6.37	10,000	63,700	43,125	Jul 19 08:35 PM
BISHOP JOHN L	Director	Jul 18 '23	Sale	30.50	10,000	305,000	33,125	Jul 19 08:35 PM
JONES EVAN/ FA	Director	Jul 18 '23	Sale	30.19	7,441	224,616	38,263	Jul 19 08:33 PM
JONES EVAN/ FA	Director	Jul 18 '23	Sale	30.16	2,324	70,090	38,439	Jul 19 08:33 PM
BISHOP JOHN L	Director	Jul 17 '23	Option Exercise	6.37	10,000	63,700	43,125	Jul 19 08:35 PM
JONES EVAN/ FA	Director	Jul 17 '23	Sale	30.07	23,949	720,106	45,704	Jul 19 08:33 PM
JONES EVAN/ FA	Director	Jul 17 '23	Sale	30.07	19,095	574,106	40,763	Jul 19 08:33 PM
BISHOP JOHN L	Director	Jul 17 '23	Sale	30.00	10,000	300,002	33,125	Jul 19 08:35 PM
Bhanji Muna	Director	Jun 16 '23	Sale	26.44	5,893	155,786	28,514	Jun 21 04:55 PM
Bhanji Muna	Director	May 30 '23	Sale	25.91	1,539	39,875	24,733	Jun 01 05:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VCYT

Veracyte Inc

Upgrade your FINVIZ experience